Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Immune checkpoint inhibitors(ICIs)have become common anti-cancer drugs, and CD19-targeted CAR-T therapies for B-cell malignant hematological diseases are becoming popular in Japan. Accompanied with such innovative progress in immunotherapy, understanding of anti-tumor immune responses have been further accelerated, and clinical trials aiming for the development of cancer immunotherapy targeting solid tumors are becoming increasingly active. Among of them, the development of"personalized cancer immunotherapy"using tumor-reactive T cells/TCRs that specifically recognize mutant antigens, or those mutant antigens has made great progress. In fact, innovative treatments for solid tumors are on the horizon. In this article, I would like to outline the background of expectations, efforts, challenges, and prospects for "personalized cancer immunotherapy".
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Impact of stress and coping strategies on quality of life in hematological malignancies: A cross-sectional study.
PLoS One
September 2025
Department of Clinical Nursing Teaching and Research Section, School of Nursing, Hebei Medical University, Shijiazhuang, China.
Background And Aims: While perceived stress and coping strategies have been established as significant determinants of quality of life (QoL) in patients with solid malignancies, their impact on hematological malignancy population have not been fully elucidated. This study aimed to examine how perceived stress and medical coping strategies interact with sociodemographic factors to influence QoL in patients with hematologic malignancies.
Methods: The study, involving 185 hematologic cancer patients in China, was conducted between August 2024 and December 2024.
Bloodstream infections in older cancer patients: epidemiology and risk factors for mortality.
J Infect Dev Ctries
August 2025
Department of Infectious Diseases and Clinical Microbiology, Etlik City Hospital, Ankara, Turkey.
Introduction: Both aging and malignancy are associated with an increased risk of infections, including bloodstream infections. Despite their clinical significance, research concentrating on the epidemiology, outcomes, and risk factors influencing mortality in older cancer patients is still limited. This study aims to examine the epidemiology of bloodstream infections and factors contributing to mortality among older cancer patients.
View Article and Find Full Text PDFCytomegalovirus and Epstein-Barr Virus reactivation in steroid-refractory immune checkpoint inhibitor colitis.
J Infect Dev Ctries
August 2025
Gastroenterology Division, Internal Medicine Department, Sultan Qaboos Comprehensive Cancer and Research Center (SQCCCRC), University Medical City (UMC), Muscat, Sultanate of Oman.
Introduction: Cytomegalovirus (CMV) and Epstein-Barr virus (EBV) reactivation are known complications in immunocompromised hosts, particularly transplant recipients. However, their occurrence and clinical implications in patients with solid tumors remain underexplored. The introduction of immune checkpoint inhibitors (ICIs) has transformed cancer therapy, but immune-related adverse events (irAEs), including colitis, are increasingly recognized.
View Article and Find Full Text PDFArtificial intelligence-based CT histogram parameters differentiating bronchiolar adenoma and lung adenocarcinomas: A two-center study.
PLoS One
September 2025
Department of Radiology, the Third Affiliated Hospital of Kunming Medical University, Yunnan, Kunming, China.
Purpose: Bronchiolar adenoma (BA) is a rare benign pulmonary neoplasm originating from the bronchial mucosal epithelium and mimics lung adenocarcinoma (LAC) both radiographically and microscopically. This study aimed to develop a nomogram for distinguishing BA from LAC by integrating clinical characteristics and artificial intelligence (AI)-derived histogram parameters across two medical centers.
Methods: This retrospective study included 215 patients with diagnoses confirmed by postoperative pathology from two medical centers.
Systematic engineering of TROP2-targeted CAR T-cell therapy overcomes resistance pathways in solid tumors.
Cancer Immunol Res
September 2025
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States.
Antibody-based therapies have revolutionized cancer treatment but have several limitations. These include: down-regulation of the target antigen; mutation of the target epitope; or in the case of antibody drug conjugates (ADCs), resistance to the chemotherapy warhead. Since TROP2-targeted therapy with ADCs yields responses in TROP2+ solid tumors but lacks the durability observed with other immunotherapy-based approaches, we developed novel TROP2-targeting chimeric antigen receptor (CAR) T cells as an alternative.
View Article and Find Full Text PDF